MetaTrader
  • Mercati
  • Grafici & Idee
  • Algo
  • Notizie
  • Store
  • Broker
  • Scarica
  • Calendario Economico
  • Segnali di Trading
  • Terminale Web
  • English English
  • Русский Русский
  • 中文 中文
  • Español Español
  • Português Português
  • 日本語 日本語
  • Deutsch Deutsch
  • 한국어 한국어
  • Français Français
  • Türkçe Türkçe
TScan Therapeutics, Inc. Common Stock

TCRX

#3152
TScan Therapeutics, Inc. Common Stock
1.06
-3.64%
Settore:
Base:
Valuta di Profitto:
Intervallo Giornaliero
1.06
1.06
Intervallo Annuale
0.88
2.57
Variazione giornaliera
-3.64%
Variazione Mensile
-4.50%
Variazione di 6 mesi
-43.32%
Variazione Annuale
-48.29%
Chiusura Precedente
1.10
Open
1.06
Bid
Ask
Low
1.06
High
1.06
Volume
6
  1. Mercati
  2. Mercato Azionario Statunitense
  3. Salute
  4. TCRX
Open full chart

Financials

Overview Estratto Conto Statistics Dividends
Quarterly Annual
Value 2021202220232024 TTM

Notizie

Investing Investing
TCRX
l’altro ieri, 12:12
TScan completa l’arruolamento nella coorte dello studio, riceve l’autorizzazione FDA
Investing Investing
TCRX
l’altro ieri, 12:09
TScan completes enrollment in trial cohort, receives FDA clearance
Zacks Zacks
RXRX TCRX
2026.02.25
Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Beats Revenue Estimates
Zacks Zacks
AGIO TCRX
2026.02.12
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue Estimates
Zacks Zacks
TCRX
2026.02.11
Sutro Biopharma (STRO) Surges 11.9%: Is This an Indication of Further Gains?
Zacks Zacks
ROIV TCRX
2026.02.06
Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates
Seeking Alpha Seeking Alpha
INCY ABVX MDGL ALKS IMTX
2025.12.16
Tracking Baker Brothers Portfolio – Q3 2025 Update (NASDAQ:INCY)
Investing Investing
TCRX
2025.12.09
Tscan Therapeutics mantiene rating Neutrale da BTIG dopo evento ASH
Investing Investing
TCRX
2025.12.09
Tscan Therapeutics stock holds Neutral rating at BTIG after ASH event
Investing Investing
TCRX
2025.12.03
TScan to host KOL event discussing updated ALLOHA trial data
Investing Investing
TCRX
2025.11.13
Morgan Stanley declassa le azioni di Tscan Therapeutics per ritardi nei trial
Investing Investing
TCRX
2025.11.13
Morgan Stanley downgrades Tscan Therapeutics stock on delayed trials

Mercati

  • Mercato Azionario Americano
  • Valute
  • Criptovalute
  • Metalli
  • Materie Prime

Grafici & Idee

  • Idee di Trading
  • Idee Educative
  • Grafici

MQL5 Community

  • Market
  • Segnali
  • Forum
  • Articoli
  • CodeBase

Notizie

  • Mercato Azionario Americano
  • Valute
  • Criptovalute
  • Metalli
  • Materie Prime

Broker

  • Tutti i Broker
  • Forex
  • Azioni
  • Metalli
MetaTrader 5
MQL5 Channels
Economic Calendar
Esclusione di Responsabilità e Informativa sui Rischi Termini di Utilizzo Contatti e richieste Legale
Copyright 2000-2026, MetaQuotes Ltd